Lokensgard J R, Hu S, Hegg C C, Thayer S A, Gekker G, Peterson P K
Neuroimmunology Laboratory, Minneapolis Medical Research Foundation, Minneapolis, Minnesota 55404, USA.
J Neurovirol. 2001 Oct;7(5):481-6. doi: 10.1080/135502801753170345.
During HIV-1 encephalitis, the chemotaxis-inducing activity of Tat may enhance the viral life cycle through recruitment of additional susceptible microglial cells to foci of infection. Benzodiazepines (BDZs) readily penetrate the blood-brain barrier and are known to possess anti-inflammatory properties. Pretreatment of human microglial cells with peripheral (Ro5-4864) and mixed (diazepam), but not central (clonazepam), benzodiazepine receptor ligands was found to potently suppress HIV-1 Tat-induced chemotaxis. Application of Tat to microglial cells evokes an increase in intracellular calcium concentration ([Ca(2+)]i) that rapidly desensitizes the cells. Diazepam's inhibitory effect was associated with its ability to block Tat-induced [Ca(2+)]i mobilization. These data support the notion that through their effects on microglia, peripheral BDZ receptor ligands could alter the neuropathogenesis of HIV-1.
在HIV-1脑炎期间,Tat的趋化诱导活性可能通过招募更多易感的小胶质细胞至感染灶来增强病毒生命周期。苯二氮䓬类药物(BDZs)能轻易穿透血脑屏障,且已知具有抗炎特性。研究发现,用外周型(Ro5-4864)和混合型(地西泮)而非中枢型(氯硝西泮)苯二氮䓬受体配体预处理人小胶质细胞,可有效抑制HIV-1 Tat诱导的趋化作用。将Tat应用于小胶质细胞会引起细胞内钙浓度([Ca(2+)]i)升高,而细胞会迅速脱敏。地西泮的抑制作用与其阻断Tat诱导的[Ca(2+)]i动员的能力有关。这些数据支持这样一种观点,即外周BDZ受体配体通过对小胶质细胞的作用,可能改变HIV-1的神经病理发生过程。